It’s great for patients and oncologists because it gives firsthand insight from healthcare professionals and patients who have used the patch.
Bedminster, NJ (PRWEB) September 1, 2010
ProStrakan, Inc. announces updates to SANCUSO.com and the release of their educational corporate SANCUSO video on YouTube. The website and corporate video provide up-to-date research and educational information about SANCUSOè (Granisetron Transdermal System), the first and only transdermal (skin) patch approved for the prevention of chemotherapy induced nausea and vomiting (CINV).(1)
Stick It to CINV
“We developed the SANCUSO corporate video as a way of promoting the zero-tolerance policy towards CINV. It’s great for patients and oncologists because it gives firsthand insight from healthcare professionals and patients who have used the patch,” explains Nelson Alfonso, Sr. Director, US Marketing, ProStrakan, Inc.
Also, ProStrakan has updated SANCUSO.com to match the new SANCUSO marketing campaign, which depicts a no-nonsense approach to CINV. ProStrakan hopes to strengthen awareness through the video and the website that CINV is unacceptable and SANCUSO is an effective and simple way of preventing CINV.
SANCUSO is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.(1) It has been used to treat patients undergoing chemotherapy regimens for breast cancer, gynecological cancers, gastrointestinal cancers, and head and neck cancers.(2) SANCUSO is included in the NCCN Guidelines for the prevention of CINV.(3)
ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets.
With more than 300 people employed by the company, ProStrakan is headquartered in Scotland with commercial operations throughout the UK and continental Europe and has a US subsidiary, ProStrakan, Inc., located in Bedminster, NJ. The company's Development group is co-located in Galashiels, Scotland and Bedminster. ProStrakan has been listed on the main London Stock Exchange since 2005.
Important Safety Information
SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.(1) Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.(1) Mild application site reactions have occurred; remove patch if severe reaction or a generalized skin reaction occurs.(1) Avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.(1)
The most common adverse reaction is constipation (5.4%).(1) SANCUSO contains granisetron.(1) Healthcare professionals should avoid prescribing any additional products that contain granisetron.
1. SANCUSO [package insert]. Bedminster, NJ: ProStrakan, Inc; 2008. 2. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. 3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.4.2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed December 3, 2009.
# # #